Tirzepatide
Compounded Dual GLP-1/GIP Receptor Agonist
A next-generation weight loss medication that targets two metabolic pathways — GLP-1 and GIP receptors — for enhanced appetite control, improved insulin sensitivity, and greater fat metabolism. In the SURMOUNT-1 trial, participants lost an average of 20–22% of body weight at the highest dose over 72 weeks when combined with lifestyle changes. Individual results vary.
Starting from $249 your first month
Then $349/mo all doses | Cancel Anytime | 3-Month & 6-Month Bundles Available
Frequency
Once Weekly
Rx Required
Yes — Prescribed Online
Pharmacy
US-Registered
Shipping
Free & Discreet
How Tirzepatide Works
Tirzepatide is a first-in-class dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. Unlike single-pathway medications, Tirzepatide activates two complementary metabolic systems simultaneously for more comprehensive weight management.
The GLP-1 pathway suppresses appetite by signaling satiety centers in the brain and slowing gastric emptying — keeping you fuller longer after meals. Meanwhile, the GIP pathway enhances metabolic efficiency, improves how your body processes fat, and supports healthier insulin responses.
This dual-action mechanism leads to greater appetite reduction and more significant fat loss than GLP-1 medications alone. Tirzepatide also helps the body use stored fat more effectively for energy, supporting gradual and sustainable weight loss when combined with lifestyle changes.
What Tirzepatide Can Do for You
Greater Average Weight Loss
In the SURMOUNT-1 clinical trial (published 2022), adults taking the highest tirzepatide dose lost an average of about 20–22% of body weight over 72 weeks alongside lifestyle changes. Individual results vary.
Dual-Pathway Action
Targets both GLP-1 and GIP receptors simultaneously for more comprehensive appetite control and metabolic support than single-pathway medications.
Improved Metabolic Health
Enhances insulin sensitivity, stabilizes blood sugar levels, and improves cholesterol and triglyceride profiles for better overall metabolic function.
Once-Weekly Injection
A single subcutaneous injection per week fits easily into any routine — no daily pills, no complicated schedules.
Physician-Monitored
Prescribed and supervised by a licensed US provider. Doses are carefully titrated based on your response and tolerance.
Sustained Energy
As metabolic function improves and excess weight decreases, many patients report more consistent energy levels throughout the day.
What to Expect
Week 1–4: Starting Low
Treatment begins at a low dose to allow your body to adjust. Most patients notice reduced appetite and fewer cravings within the first 2 weeks. Mild GI side effects are common but typically improve.
Week 4–12: Accelerating Results
Your dose is gradually increased on a monthly basis. Weight loss becomes more noticeable as the dual pathways work together. Appetite suppression strengthens and metabolic improvements begin.
Week 12+: Reaching Your Stride
At your target dose, consistent weight loss continues with well-managed hunger. Your provider monitors labs and adjusts as needed to optimize long-term results.
Important Safety Information
Compounded tirzepatide is not FDA-approved as a finished drug product. It is prepared by a US-licensed compounding pharmacy under a prescription from an independent network of US-licensed providers. Common side effects include nausea, diarrhea, decreased appetite, vomiting, and constipation — most are mild and improve with dose titration.
Tirzepatide should not be used by individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Not recommended during pregnancy or breastfeeding. Always consult your healthcare provider.
Ready to take the next step?
Complete a brief online evaluation to see if Tirzepatide is right for you. A licensed provider will review your health profile and create a personalized plan.
FAQ